Two large retrospective cohort studies presented by the team at Mayo Clinic, Rochester MN examine the burden of stroke, as well as overall and cause-specific mortality in people with RA (POS0591 and POS0592).

Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.

Do the clinical features of axSpA patients with and without IBD differ? In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in

Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.

Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few

Several abstracts are presenting new compounds, targeting either RA well-known inflammatory pathways or offering new mechanisms of action or therapeutic sequences; these are summarized below.

Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab. Despite this, some patients remain refractory to these effective therapies.

On the first day of EULAR 2024, I am debating Janet Pope. To make it more challenging, it’s about JAK inhibitor safety, and I have been allocated to argue against the regulatory safety warning and the randomised controlled trial that supports it.